Orum Therapeutics to Participate at Investor Conferences in September

BOSTON & DAEJEON, South Korea–(BUSINESS WIRE)–#ADC—Orum Therapeutics, a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the Company�s leadership will participate in the following investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference

Forum: 1×1 In-Person Meetings

Dates: Monday, September 12th to Wednesday, September 14, 2022

Location: New York, NY

Baird’s Global Healthcare Conference 2022

Forum: Presentation and 1×1 In-Person Meetings

Dates: Tuesday, September 13th to Wednesday, September 14, 2022

Location: New York, NY

The presentation will take place at 4:20 pm ET on September 13th.

UBS Virtual Biotechnology Private Company Symposium

Forum: 1×1 Virtual Meetings

Date: Wednesday, September 21 to Thursday, September 22, 2022

About Orum’s GSPT1 Platform Using the TPD² Approach

Orum’s GSPT1 platform uses the Company’s unique Dual-Precision Targeted Protein Degradation (TPD²™) approach to build novel targeted protein degraders (TPD) combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-specific TPD for the treatment of cancer. The company has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to cancer cells and degrade the intracellular target protein GSPT1 and cause tumor cell death.

About Orum Therapeutics

Orum Therapeutics is a private, clinical stage biotech pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD² approach to provide dual-precision, antibody-enabled targeted protein degraders for cell-specific delivery. The Company’s proprietary platforms generated using the TPD² approach include the GSPT1 platform, which generates first-in-class antibody drug conjugates. The first therapeutic candidates from the GSPT1 platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Boston, US and Daejeon, South Korea. For more info, visit www.orumrx.com.

Contacts

Corporate: Kyuri Kim Ph.D., Senior Manager, Business Development, Orum Therapeutics, contact@orumrx.com

Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., +1-858-344-8091, jessica@litldog.com